Compare Ascendis Pharma A/S (ASND) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Exxon Mobil Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Exxon Mobil Corporation trades at $140.48 (market cap $575.65B). The key difference: Exxon Mobil Corporation is far larger — about 32.4× Ascendis Pharma A/S's market cap, and Exxon Mobil Corporation pays a 2.97% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | XOM | |
|---|---|---|
Market Cap | $17.74B | $575.65B |
Sector | Health | Energy |
52-Week High | $277.18 | $171.52 |
52-Week Low | $163.32 | $105.83 |
Enterprise Value | $18.11B | $614.88B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ExxonMobil (XOM) trades at $138.83, up 1.06% with a bearish technical signal despite recent earnings beats. The company shows declining revenue ($323.9B in 2025) and profit margins (8.9% in 2025) but maintains strong cash flow from operations ($52B). Analyst consensus is mixed with 43% buy ratings and a $169.30 price target, while recent news highlights Exxon's Permian Basin advantages and warnings about potential oil price spikes to $160 per barrel.
XOM faces headwinds from declining profitability but offers value through its low breakeven Permian operations and dividend yield. The stock's upside depends on oil price stability and execution of production growth targets, while risks include volatile energy markets and ongoing margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
